An immunogenic personal neoantigen vaccine for patients with melanoma.
about
Tools to define the melanoma-associated immunopeptidome.Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling.The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.Virus like particles as a platform for cancer vaccine development.'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer.Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles.New trends in antitumor vaccines in melanoma.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.The Future of Immunotherapy: A 20-Year Perspective.An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes.The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction.Membranal and blood-soluble HLA class II peptidome analyses using data-dependent and independent acquisition.Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes.Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?Hitting the Target: How T Cells Detect and Eliminate Tumors.Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.Therapeutic Cancer Vaccines: How Much Closer Are We?Informatics for cancer immunotherapy.Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy.Cancer immunotherapy beyond immune checkpoint inhibitors.Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.Present status and future perspective of peptide-based vaccine therapy for urological cancer.mRNA vaccines - a new era in vaccinology.Cancer Immunotherapy Targeted Glypican-3 or Neoantigens.Towards personalized, tumour-specific, therapeutic vaccines for cancer.Neoantigens in the immuno-oncology space.Advances in immunotherapy for pediatric acute myeloid leukemia.Progress in biopharmaceutical development.Immune correlates of clinical outcome in melanoma.Inhibitors of the PD-1 Pathway in Tumor Therapy.Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial.The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy.
P2860
Q38650013-AA9F99D0-076F-445B-93B8-EA23C8A86950Q41444208-42A78826-12EF-4664-AEA4-D5FD18B2D20AQ41673084-8B73673F-A6D6-4F96-95D7-20EEDA404710Q45324534-7E109BA3-C56E-460A-B9DC-8DBE49FDF082Q45718710-8E81C38A-4D03-4AF2-B1F5-57DC4EA1991BQ45875006-106C9E8F-C684-44B3-9D71-9992E70D8168Q46429495-D09D0C3A-E0CB-4F22-8212-63E94EBD5062Q46793262-D398246C-B275-4DC6-9146-1DD14688581FQ47093855-4EA4FC4D-DC78-43B9-B30A-95D25EA3D059Q47115040-F550481E-0C3D-470B-9C9B-C06052D4B449Q47120629-18B0BD48-AA48-4DE4-B000-D316343E0136Q47133741-53A80A6E-6622-465B-AFF5-73D0128E237AQ47135720-07EBCB2A-D326-481A-BC20-879505F7CC93Q47150991-A7889E45-6567-4C49-8AC6-8980C00D548CQ47162933-1720980F-703E-4A1E-81FF-B5BEC410DEFDQ47162995-9BBF1F2D-B9E1-49C3-823F-3F70FCAB9B01Q47190955-DDF75974-8B68-4AE7-99F4-2B7FC08969DDQ47191093-4AE1E461-91D1-49F7-B606-169EFA93818DQ47220965-9D87577E-D843-43C0-B291-2087AFD33B60Q47221163-9E5F88F5-C16B-44C2-96CF-EB15DB37711FQ47222791-C602B255-9370-41F0-80D3-9214B194F68CQ47224779-189C611C-72BD-4CF2-900D-023E9F9893EBQ47227422-71247E60-9AFE-403D-80F2-3039D36CB83FQ47235984-7B8E375A-DA23-415B-8741-35E0613E4F48Q47290509-ABBDFCDF-C1B5-4F52-BC35-EFFD4D51AF47Q47304240-2783BF45-2658-4465-9663-CAD5D99C036CQ47320909-BDF643B1-2425-4B79-8FB4-41E798C55CA8Q47554248-89A95DD0-B7CD-42C3-AD08-C35878EB8B51Q47716902-2C106E12-9348-4A5A-86C7-443F8CF84F39Q47725715-9E1F138F-8348-4347-9BBD-3309B30DDE93Q47736893-F793ACAA-2756-43A5-98DA-0D9582CCF565Q47760070-AEBD0A3D-CAC2-4B1C-A622-BF4178F6436DQ47789519-A7795840-641B-470D-AA6A-A193660A4C42Q47915799-45522AAA-FFEE-416A-A8FD-74ABC69AD728Q47930962-A5517E71-3CD7-4E15-A13C-1F29C65FC719Q48253463-E6027F6C-E4E7-4F72-B021-237E7F37AF3CQ48257119-697B1C1A-5E6A-435F-BFD2-F2BB7B3F932DQ48293633-AFD190A9-91EA-4090-B87E-194063B7CBCCQ49237244-A9325B20-4B0C-4839-9791-D296C1E1CBADQ49307766-D7192DBF-EF04-4FC2-AFC6-D59E62941C0E
P2860
An immunogenic personal neoantigen vaccine for patients with melanoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
An immunogenic personal neoantigen vaccine for patients with melanoma.
@en
type
label
An immunogenic personal neoantigen vaccine for patients with melanoma.
@en
altLabel
An immunogenic personal neoantigen vaccine for patients with melanoma
@en
prefLabel
An immunogenic personal neoantigen vaccine for patients with melanoma.
@en
P2093
P2860
P50
P356
P1433
P1476
An immunogenic personal neoantigen vaccine for patients with melanoma.
@en
P2093
Adrienne Luoma
Andres M Salazar
Anita Giobbie-Hurder
Catherine J Wu
Charles H Yoon
Christina Chen
Dan H Barouch
David J Bozym
David J Lieb
Derin B Keskin
P2860
P2888
P304
P356
10.1038/NATURE22991
P407
P577
2017-07-05T00:00:00Z